Reports / Gastroenterology Reports / RealTime Dynamix: Inflammatory Bowel Disease US
RealTime Dynamix: Inflammatory Bowel Disease US (quarterly)
The RealTime Dynamix™: Inflammatory Bowel Disease (US) report series provides a detailed and timely look at current and future trends in the IBD market and the effects of the future shifting landscape. The quarterly releases allow for close monitoring and trending of key performance metrics. In addition to the fixed trended measures, the report also includes variable content addressing key current issues updated quarterly. The rapid field-to-insight turnaround time, highly relevant content, and unparalleled knowledge of the IBD market make this an essential tool for companies competing in the space, as well as those with near term plans to enter it.
This quarterly report has been fielded since Q1 2016.
Learn more about RealTime Dynamix™ reports here.
- What are the continued adoption and share trends for Stelara since the late 2016 launch and what products are losing to this new entrant?
- How will the much anticipated launch of oral Xeljanz disrupt the biologic segment and in what line of therapy will it see the most use?
- What will the trajectory of Entyvio be in the face of Xeljanz for UC in addition to the growing competition from Stelara?
- How is the adoption of alternative MOAs changing the practice of sequencing TNF inhibitors?
- What are key barriers across brands?
- What biologic brands do gastroenterologists prefer for specific IBD patient types?
- How do key IBD brands perform on select attributes?
- How is patient preference guiding brand choice?
- To what degree are infliximab biosimilars impacting the use of branded Remicade and what pressure is being placed upon prescribers to utilize biosimilars?
- What can new entrants learn from the current payer access barriers for inline brands in order to plan for successful launches?
AbbVie (Humira), Biogen (Tysabri), Janssen (Remicade, Stelara), Merck (Renflexis [infliximab biosimilar]), Pfizer (Inflectra [infliximab biosimilar]), Takeda (Entyvio), UCB (Cimzia)
AbbVie (upadacitinib), Arena Pharma (etrasimod), Celgene (Otezla, ozanimod), Eli Lilly (mirikizumab), Gilead (filgotinib), Pfizer (Xeljanz), Roche/Genentech (etrolizumab)
Uptake of Biosimilars in the EU5 Blunts Share of AbbVie’s Humira and Merck’s Remicade in the Crohn’s Disease and Ulcerative Colitis Markets, While a Black Cloud of Safety Concerns Still Follows Pfizer’s Xeljanz – July 16, 2019
US Gastroenterologists Report VARSITY Trial Data and JAK Inhibitor Safety Concerns Will Impact Their Prescribing Behavior in Ulcerative Colitis, with Potential Implications for Crohn’s Treatment – June 5, 2019